Drug combination delivers promising survival gains in advanced endometrial cancer

The Medical News ·
Health & Medicine United Kingdom

An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.

Read original article on The Medical News →

Related news